31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic … (NCT03843710) | Clinical Trial Compass
WithdrawnPhase 2
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)
Stopped: Study execution discontinued at this time.
United States0Started 2020-03
Plain-language summary
REPAIR-ALS is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Amyotrophic Lateral Sclerosis (ALS) within twelve (12) months of Screening. The primary endpoint is the ratio of the oxidized to reduced form of nicotinamide adenine dinucleotide (NAD+:NADH) measured non-invasively by 31phosphorous magnetic resonance spectroscopy (31P-MRS).
Who can participate
Age range35 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Able to understand and give written informed consent.
✓. Male or female patients aged 35 years or greater (inclusive) and less than 75 years of age at the time of ALS diagnosis.
✓. Patients with a confirmed ALS diagnosis: "definite ALS" or "probable ALS" or "possible" diagnostic criteria per the revised El Escorial Criteria as determined by a neurologist subspecializing in ALS (e.g., the Principal Investigator by study site).
✓. Stable background therapy (e.g., stable dosing of riluzole within the prior 6-weeks) per Investigator discretion.
✓. At the time of Screening disease duration less than or equal to 24-months from symptom onset OR within 12-moths of a confirmed ALS diagnosis.
✓. Forced vital capacity (FVC) \>/= 60% of predicted value as adjusted for gender, height, and age at the Screening Visit.
✓. Patients who are ambulatory (e.g., normal ambulation, early ambulation difficulties, or walks with assistance) on the ALSFRS-R scale.
. At Screening patients who utilize, or in the Investigator's judgment will be imminently dependent upon during the course of this study:
✕. Non-invasive ventilation
✕. Gastrostomy (e.g., use of percutaneous endoscopic gastrostomy tube)
✕. Use of wheel chair
✕. Patient who have previously undergone tracheostomy.
✕. Patient with a history of significant other major medical condition based on the Investigator's judgment.
✕. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or study procedures.
✕. Patient with clinically significant abnormalities in hematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation.